|Bid||0.0000 x 21500|
|Ask||2.2200 x 36900|
|Day's range||2.0400 - 2.2000|
|52-week range||1.6400 - 3.6160|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.55|
Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cannabis stocks have become quite the hot item on the stock exchange lately, a trend that stretched into Monday's trading. Canadian weed companies also landed well in positive territory, with Organigram (NASDAQ: OGI) advancing at an 18% clip and Cronos Group (NASDAQ: CRON) rising by 9%. It's no accident that these rises came just before the influential rules committee of the U.S. House of Representatives is set to meet on an appropriations bill.
Cronos Labs has also signed up Google Cloud, Amazon Web Services and blockchain security specialists PeckShield and Certik as mentors for the program.